Fig. 3: HA-K130N and HA-K130E mutations confer cross-resistance to multiple neuraminidase inhibitors. | Nature Communications

Fig. 3: HA-K130N and HA-K130E mutations confer cross-resistance to multiple neuraminidase inhibitors.

From: A primary oseltamivir-resistant mutation in influenza hemagglutinin and its implications for antiviral resistance surveillance

Fig. 3: HA-K130N and HA-K130E mutations confer cross-resistance to multiple neuraminidase inhibitors.

a Plaque-reduction assay of the A/California/07/2009 wild-type (Cal09-WT) virus and HA-K130N and HA-K130E mutants in the presence of zanamivir. This assay was conducted in the absence (0 μM) or presence of 0.01, 0.1, 1, or 10 μM zanamivir. b Plaque diameters (mm) corresponding to panel (a). c Plaque-reduction assay of the Cal09-WT virus and HA-K130N and HA-K130E mutants in the presence of peramivir. This assay was performed in the absence (0 μM) or presence of 0.01, 0.1, 1, or 10 μM peramivir. d Plaque diameters (mm) of the viral plaque in panel (c). Recombinant viruses generated from two independent rescue experiments were subjected to plaque-reduction experiments. Each dot represents the diameter (mm) of a single plaque (n = 20). Source data are provided as a Source Data file.

Back to article page